Shares of Moderna rose by a staggering 29.17% in 30 days from $134.39 to $173.59 at 20:54 EST on Tuesday, after two successive sessions in a row of gains. NASDAQ Composite is dropping 1.88% to $13,633.50, after three consecutive sessions in a row of losses.

Moderna’s last close was $186.02, 9.03% under its 52-week high of $189.26.

Moderna’s Sales

Moderna’s sales growth is 24182.2% for the present quarter and 6321.4% for the next. The company’s growth estimates for the ongoing quarter and the next is 782.9% and 1983.9%, respectively.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 3960.8%, now sitting on 803.4M for the twelve trailing months.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $173.59 at 20:54 EST, below its 52-week high of $189.26 and way higher than its 52-week low of $30.98.

Moderna’s Moving Average

Moderna’s worth is way above its 50-day moving average of $143.54 and way above its 200-day moving average of $119.02.

Previous days news about Moderna

Moderna to supply up to 500 million vaccine doses to covax. According to Bloomberg Quint on Monday, 3 May, "Rich countries last year snapped up vaccine supplies from Moderna and others, and the U.S. alone has already administered more than 240 million doses. ", "The terms of the agreement with Gavi weren’t disclosed, though Moderna said it’s offering the vaccine at the company’s "lowest-tiered price."

Moderna to supply 500 million Covid-19 vaccine doses on behalf of covax. According to MarketWatch on Monday, 3 May, "We recognize that many countries have limited resources to access COVID-19 vaccines," said Moderna Chief Executive Stéphane Bancel. "

Moderna to deliver Covid-19 vaccine to hard-hit developing world. According to The Wall Street Journal on Monday, 3 May, "Covax will retain an option to purchase another 466 million doses in 2022, according to a statement by Moderna and Gavi, one of the organizations behind the vaccine aid program."

Moderna to boost Covid-19 vaccine production at Massachusetts site by 50%. According to MarketWatch on Tuesday, 4 May, "Shares of Moderna Inc. were down 0.3% in premarket trading on Tuesday after the company said it will double the size of its manufacturing space at its facility in Norwood, Mass., essentially allowing for a 50% increase in the production of its COVID-19 vaccine there. ", "We believe that this investment and expansion at our technology center will allow us to continue to optimize our mRNA products as we explore new pharmaceutical delivery forms such as prefilled syringes and lyophilized products," Moderna CEO Stéphane Bancel said in a news release. "

More news about Moderna.


Please enter your comment!
Please enter your name here